Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized hemodynamically guided antihypertensive treatment in pregnant women with mild to moderate gestational hypertension
NL-OMON53093Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methyldopa, nifedipine and carvedilol in pregnancy-induced hypertension (PIH) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Incidence of progression to severe hypertension and/or preeclampsia. Started Jan 2016; status: recruiting.
02
Drugs
methyldopanifedipinecarvedilol
03
Conditions
pregnancy-induced hypertension (PIH)
Beyond the preview
Go deeper on NL-OMON53093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53093.